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 Hypertension, an increase in blood pressure, can lead to many serious 
complications, one of which is heart failure. Angiotensin (Ang) II is associated with 
hypertension; specifically, the Ang II receptor type 1 (AGTR1) is known to cause 
vasoconstriction. Currently, medication is available to lower blood pressure, but it 
presents limitations. For this reason, naturally occurring substances are being examined 
in combination with antihypertensive medication. Two polyphenols that have been shown 
to lower blood pressure are resveratrol and pterostilbene. Although they present a 
possible ability to lower blood pressure, they both require a more intensive understanding 
of how the compound works to reduce blood pressure. The purpose of the study was to 
examine the effect of resveratrol and pterostilbene at the receptor level for the first time 
using parallel receptor-ome expression and screening via transcriptional output- 
transcriptional activation following arrestin translocation (PRESTO-TANGO). This novel 
method will allow AGTR1 activation to be measured through luminescence. This study 
demonstrated that resveratrol alone at concentrations of 50 μM, 100 μM, and 200 μM 
activates AGTR1 and also when combined with Ang II. Ang II with 50 μM and 100 μM 
resveratrol had a greater activation than Ang II alone. It was also found that 20 μM 
pterostilbene combined with Ang II activated AGTR1 and had a greater activation than 
Ang II alone. Although the results were not statistically significant, the trends suggested 
that resveratrol and pterostilbene do promote the activation of AGTR1. Since this is the 
first time that the effect of resveratrol and pterostilbene on AGTR1 has been examined, 
more studies will need to be conducted at the receptor level to understand the 




 The mission statement of the Lakehead University Department of Biology states, 
“Faculty and students in the Department of Biology are bound together by a common 
interest in explaining the diversity of life, the fit between form and function, and the 
distribution and abundance of organisms.” This research project was part of the human 
sciences, specifically in regard to the study of hypertension. It aimed to investigate two 
naturally occurring polyphenols, resveratrol and pterostilbene, at the receptor level using 
the PRESTO-TANGO method. By analyzing the angiotensin II receptor type 1 (AGTR1) 
activation, it was concluded that the increase in AGTR1 receptor activation by 
angiotensin II was not attenuated by resveratrol and pterostilbene . Future studies are 
directed towards investigating the role of these polyphenols at receptor level.    
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Ang – angiotensin 
ACE – angiotensin-converting enzyme 
AGTR1 – angiotensin II receptor type 1 (human) 
AGTR2 – angiotensin II  receptor type 2 (human) 
agtr1 – angiotensin II receptor type 1 (rodent) 
agtr1a – angiotensin II  receptor type 1 subunit a (rodent) 
agtr1b – angiotensin II receptor type 1 subunit b (rodent) 
agtr2 – angiotensin II receptor type 2 (rodent) 
ARB – angiotensin receptor blockers 
BrdU – bromodeoxyuridine 
DMEM – Dulbecco’s Modified Eagles Medium 
GPCR – G-protein-coupled receptor 
FBS – fetal bovine serum 
LB – Lysogeny Broth 
PBS – phosphate buffered saline 
PRESTO-TANGO – parallel receptor-ome expression and screening via transcriptional 
output- transcriptional activation following arrestin translocation 
RAAS – renin-angiotensin-aldosterone system 





Table of Contents 
Abstract ............................................................................................................................... i 
Lay Summary .................................................................................................................... ii 
Acknowledgements .......................................................................................................... iii 
Abbreviations ................................................................................................................... iv 
List of Tables .................................................................................................................. viii 
List of Figures ................................................................................................................... ix 
Chapter 1: Introduction ................................................................................................... 1 
1.1 Hypertension ............................................................................................................. 1 
1.2 Angiotensin II ............................................................................................................ 2 
1.3 G-Protein-Coupled Receptors of Angiotensin II ....................................................... 4 
1.4 PRESTO-TANGO System .......................................................................................... 8 
1.5 Resveratrol .............................................................................................................. 11 
1.6 Pterostilbene............................................................................................................ 14 
1.7. Rationale ................................................................................................................ 16 
1.8 Hypothesis ............................................................................................................... 17 
1.9 Specific Aims ........................................................................................................... 17 
Chapter 2: Methods ........................................................................................................ 18 
2.1 Transformation of Competent Cells ........................................................................ 18 
2.2 Cell Culture Methods .............................................................................................. 19 
2.3 Transfection ............................................................................................................. 19 
vi 
 
2.4 Treatment ................................................................................................................ 20 
2.4.1 Resveratrol Treatment ...................................................................................... 20 
2.4.2 Ang II Treatment ............................................................................................... 20 
2.4.3 Losartan Treatment .......................................................................................... 20 
2.4.4 Ang II + Losartan Treatment............................................................................ 21 
2.4.5 Ang II + Resveratrol Treatment ....................................................................... 21 
2.4.6 Pterostilbene Treatment ................................................................................... 21 
2.4.7 Ang II + Pterostilbene ...................................................................................... 21 
2.5 Cell and Viability Test ............................................................................................. 22 
2.6 Reading Luminescence ............................................................................................ 22 
2.7 BrdU Fixing and Reading ....................................................................................... 22 
2.8 Statistics .................................................................................................................. 24 
Chapter 3: Results........................................................................................................... 25 
3.1. Results of Optimization .......................................................................................... 25 
3.2. Optimized Results ................................................................................................... 56 
Chapter 4: Discussion ..................................................................................................... 63 
4.1 Optimization of System ............................................................................................ 64 
4.2 Optimized System .................................................................................................... 70 
Chapter 5: Conclusion .................................................................................................... 73 
Chapter 6: References .................................................................................................... 74 
Chapter 7: Appendix ...................................................................................................... 81 
7.1 Formulas ................................................................................................................. 81 
vii 
 
7.1.1 Cell Density ...................................................................................................... 81 
7.1.2 Cell Viability .................................................................................................... 81 
7.2. BrdU Results .......................................................................................................... 82 
7.2.1 Control .............................................................................................................. 82 
7.2.2 Angiotensin II ................................................................................................... 83 
7.2.3 Losartan ............................................................................................................ 84 
7.2.4 Angiotensin II + Losartan ................................................................................ 85 
7.2.5 Resveratrol 50 μM ............................................................................................ 86 
7.2.6 Resveratrol 100 μM .......................................................................................... 87 
7.2.7 Resveratrol 200 μM .......................................................................................... 88 
7.2.8 Resveratrol 400 μM .......................................................................................... 89 
7.2.9 Angiotensin II + Resveratrol 50 μM ................................................................. 90 
7.2.10 Angiotensin II + Resveratrol 100 μM ............................................................. 91 
7.2.11 Angiotensin II + Resveratrol 200 μM ............................................................. 92 














List of Tables 
Table 1. Cell Density and Viability 1. .............................................................................. 40 
Table 2. Cell Density and Viability 2. .............................................................................. 46 
Table 3. Cell Density and Viability 3. .............................................................................. 48 
Table 4. Cell Density and Viability 4. .............................................................................. 50 
Table 5. Cell Density and Viability 5. .............................................................................. 52 
Table 6. Cell Density and Viability 6. .............................................................................. 54 
Table 7. Cell Density and Viability Trial 1....................................................................... 58 
Table 8. Cell Density and Viability Trial 2....................................................................... 59 
Table 9. Cell Density and Viability Trial 3....................................................................... 60 




List of Figures 
Figure 1. Renin-angiotensin-aldosterone pathway depicting the formation of Ang II. ...... 4 
Figure 2. Ang II major receptors in rodents. ....................................................................... 6 
Figure 3. PRESTO-TANGO system. ................................................................................ 11 
Figure 4. Mechanism of PRESTO-TANGO system. ........................................................ 11 
Figure 5. Molecular structure of resveratrol. .................................................................... 12 
Figure 6. Molecular structure of resveratrol and pterostilbene. ........................................ 15 
Figure 7.  Optimization steps. ........................................................................................... 25 
Figure 8. Effect of resveratrol on AGTR1 activation. ...................................................... 35 
Figure 9. Effect of losartan on AGTR1 activation. ........................................................... 36 
Figure 10. Effect of FBS on AGTR1 activation. .............................................................. 37 
Figure 11. Effect of FBS on AGTR1 activation and control cells. ................................... 38 
Figure 12. Effect of FBS, filter sterilized FBS, and no FBS on AGTR1 activation. ........ 39 
Figure 13. Effect of dialyzed FBS on AGTR1 activation. ................................................ 41 
Figure 14. Effect of varying concentrations of AGTR1 plasmids. ................................... 42 
Figure 15. AGTR1 luminescence over time. .................................................................... 43 
Figure 16. Ang II luminescence over time........................................................................ 44 
Figure 17. Effect of losartan in the presence of Ang II on AGTR1 activation. ................ 45 
Figure 18. Effect of resveratrol in the presence of Ang II on AGTR1 activation. ........... 47 
Figure 19. Effect of varying concentrations of pterostilbene on AGTR1 activation. ....... 49 
Figure 20. Effect of 20 μM pterostilbene in the presence of Ang II on AGTR1 activation.
 ................................................................................................................................... 51 
x 
 
Figure 21. Effect of resveratrol 100 μM in the presence of Ang II on AGTR1 activation.
 ................................................................................................................................... 53 
Figure 22. Effect of varying concentrations of pGL4.54 on AGTR1activation. .............. 55 






















Chapter 1: Introduction 
1.1 Hypertension 
 Cardiovascular disease is one of the leading causes of death worldwide [1]. 
Cardiovascular disease can include coronary artery disease, heart failure, cardiac arrest, 
ischaemic stroke, and ventricular arrhythmias [1]. Hypertension has been defined as 
having a high blood pressure, with a systolic blood pressure ≥ 140 mmHg and/or a 
diastolic pressure ≥ 90 mmHg [2, 4]. It is a chronic condition that can lead to serious 
complications and is a major risk factor of cardiovascular disease [1, 2-4]. Blood pressure 
is dependent on cardiac output and systematic vascular resistance [5]. For example, the 
narrowing of blood vessels can cause the heart to work harder to pump blood, resulting in 
an increased blood pressure.  
 Hypertension can develop in one of two ways, namely, primary hypertension and 
secondary hypertension. Primary hypertension, also known as essential hypertension, has 
no known cause, meaning that hypertension develops over time [4, 6]. It is believed to be 
a combination of genetic, environmental, and behavioral factors [4]. Along with aging, 
lifestyle factors such as decreased exercise and increased stress are thought to contribute 
to increase blood pressure [7]. Secondary hypertension occurs when disease is the result 
of an identifiable cause, such as through thyroid and renal disease [6].  
 To manage hypertension and prevent future complications associated with high 
blood pressure, standard treatment options are available. Treatment of hypertension 
involves changes in lifestyle and the use of blood pressure-reducing medication [5, 8]. By 
changing lifestyle habits, such as reducing sodium intake and alcohol consumption, and 
by increasing physically activity, blood pressure can be reduced in some instances [8]. 
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Lifestyle changes, in combination with blood pressure-reducing medications, are also 
commonly used.  
  Multiple pharmacologically produced medications such as α and β-blockers, 
angiotensin (Ang)II receptor blockers (ARBs), diuretics, calcium channel blockers, Ang-
converting enzyme (ACE) inhibitors and  direct vasodilators can help to decrease blood 
pressure [5, 9]. Two major classes of antihypertensive medications that target the renin-
angiotensin-aldosterone system (RAAS) include ACE inhibitors and ARBs [10]. ACE 
inhibitors such as benazepril and captopril inhibit the ACE, which then inhibits the 
formation of Ang II [10]. ARBs such as losartan and candesartan block the binding  of 
Ang II to Ang II receptors [10].  
The combination of ACE inhibitors and ARBs have been shown in a meta-
analysis conducted in various populations to reduce blood pressure, but no long-term 
effects were concluded from this study [10]. It has been advised that treatment of 
hypertension should not include ARBs/ACE inhibitors in combination [10]. Although 
medications are available, some drugs might not fully block binding, and medications can 
present adverse side effects [5, 10, 11]. Therefore, naturally occurring compounds are 
being studied as an alternative.  
1.2 Angiotensin II  
 Ang II is a octapeptide hormone that plays an important role in regulating blood 
pressure and in the cardiovascular system because of its ability to cause the 
vasoconstriction of arteries and veins [12, 13].  It is part of the RAAS, which is 
controlled through the actions of the cardiovascular system; the central nervous system; 
and the kidneys, which allow blood pressure homeostasis to be controlled [12, 14, 15].  
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 The RAAS pathway, depicted  in Figure 1, starts with the formation of 
angiotensinogen, the precursor to Ang I [12]. Angiotensinogen, a Serpin A8 protein, is 
produced mainly in the liver [12,15]. When it combines with renin, which is produced 
largely in the kidneys, it is converted into Ang I [15]. The renin allows for the 10 amino 
acid cleavage from the N-terminus of the angiotensinogen [12, 15]. It should be noted 
that Ang II levels are dependent on renin levels because renin is a rate-limiting step in 
RAAS [14]. Ang II is converted from Ang I by the removal of two amino acids from the 
C-terminus by ACE [12, 13, 15]. Ang II is the major biological product of RAAS, 
although Ang II can be converted further into Ang 1-7 [15]. It works through two specific 
G-protein-coupled receptors (GPCRs) known as angiotensin II receptor type 1 (AGTR1) 
and angiotensin II receptor type 2 (AGTR2) [15, 16]. Ang II is known to mediate cardiac 







Figure 1. Renin-angiotensin-aldosterone pathway depicting the formation of Ang II. 
Adapted from M. Sparks et al. Comprehensive Physiology (2014). Cleavage of 
angiotensinogen by renin forms Ang I. The ACE then converts Ang I into Ang II. The 




1.3 G-Protein-Coupled Receptors of Angiotensin II  
 GPCRs also are known as a seven-transmembrane domain receptors that are 
capable of turning an extracellular signal into an internal signal inside the cell [17- 20]. 
GPCRs are involved with facilitating many physiological processes, specifically 
processes caused by hormones, neurotransmitters, and the environment [18]. For this 
reason, they are considered important drug targets [18, 19]. The main purpose of GPCRs 
is to bind to their agonist to activate the G-protein, which results in activating 
downstream signaling pathways [19]. It has been estimated that there are at least 800 
human GPCRs, but not all functions are known because of limited structural detection 
methods [19, 20]. Specifically, GPCRs can have different signalling and transduction 
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pathways, making it difficult to determine the actual effect of just ligand and GPCR 
binding without system interference [18].  
 Ang II, the major active product of the RAAS, is known to mediate blood 
pressure [12, 21].  Ang II can be found in different tissues types, including cardiac tissue 
and is involved in cardiac remodeling [21, 22]. Ang II works through two specific 
GPCRs, known as AGTR1 and AGTR2 [22]. Other proposed receptors include Ang II 
receptor type 3 (AGTR3) and Ang II receptor type 4 (AGTR4) [22]. However, AGTR1 
and AGTR2 are the major receptors because they meet the criteria of being operational, 
having transduction and structural compatibility [22]. The effects of Ang II are mediated 
through AGTR1 and opposed by AGTR2 [23]. The reported physiological outcomes of 
AGTR1 activaition by Ang II include being vasoconstrictive, hypertrophic, 
antinatriuretic, antidiuretic (via increased antidiuretic hormone release), proinflammatory, 
prooxidative stress, profibrotic, and prothrombotic [24]. The reported physiological 
outcomes of AGTR2 activaition by Ang II include being vasodilative, antiproliferative, 
proapoptotic [24]. Chronic exposure to Ang II downregulates its receptors [21]. It should 
be noted that AGTR1nomeclature is different in animals and humans. AGTR1 in rodents 
is denoted in literature as Agtr1 and contains two subunits, Agtr1a and Agtr1b (Figure 2) 






Figure 2. Ang II major receptors in rodents. Agtr1a and Agtr1b are the subunits of Agtr1 
and Agtr2 in rodents [21, 22]. 
 
  
 In humans, AGTR1 is located on chromosome 3 [21, 22]. It is found in a variety 
of tissues throughout the body, such as the brain, lung, heart and blood vessels [21]. The 
approximate molecular mass of AGTR1 is 40 kDa [21, 22]. AGTR1 binds with both 
agonists and antagonists [25]. Binding to a receptor is determined by specific residues 
that are located either on the extracellular region or on the transmembrane domain [21]. 
The effect of AGTR1 when activated though binding by an agonist such as Ang II 
promotes vasoconstriction. AGTR1 also can be upregulated and downregulated by 
agonists [21]. When Ang II is increased for a short time, AGTR1 is increased [21]. 
However, Ang II is considered a downregulator of AGTR1 when exposed chronically, 
possibly due to desensitaization  [21]. Blocking agents can be used to prevent an agonist 
from binding to AGTR1 [22]. For example, losartan, an Ang II receptor blocker, can be 
used to block the agonist [22].  
In rodents, Agtr1a and Agtr1b are located on chromosomes 17 and 2 [21]. The 
approximate size of Agtr1a is 84kb, and the approximate size of Agtr1b is 15kb [22]. 
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Agtr1a is expressed throughout the body, including the heart [22]. Studies have suggested 
that the heart contains only Agtr1a , with Agtr1b being confined to the areas of the 
adrenal gland, brain, and testis [ 22]. There is a 95% similarity between their amino acid 
sequences, making them almost indistinguishable [21]. However, it has been shown that 
Agtr1a plays a larger role in the regulation of blood pressure, although research has 
suggested that they are functionally the same [21].  
When AGTR1 binds to Ang II, it induces multiple signalling pathways that 
include both G protein- and non-G protein-related signalling [21]. The major pathways 
that are activated to produce the functions associated with AGTR1 are through 
phospholipase C, phosphoinositide hydrolysis and Ca
2+
 signalling [22]. This binding also 
signals cross-talk between tyrosine kinases [21]. Reactive oxygen species produced by 
activation of NAD(P)H oxidases are associated with the effects produced by Ang II 
binding to AGTR1 [21]. Serine/Threonine kinases (MAPK pathways) and the Jak/STAT 
pathway also are activated [21, 22].  
 In humans, the approximate molecular mass of AGTR2 is 41kDa [21]. The 
AGTR2 encoding gene is located on chromosome X in humans and in rodents [21, 22]. It 
is approximately 34% similar to AGTR1 but displays different functions than AGTR1 
[21]. Ang II, when bound to AGTR2, is known to be a vasodilator [24]. It also is capable 
of producing antiproliferative and proapoptotic effects [21, 24]. It has been thought that 
AGTR2 plays a large role in fetal development because it is ubiquitously expressed at 
birth and then declines in some tissues [21, 22]. AGTR2 has been shown in the heart to 
remain at consistent levels [22]. However, it has been thought that AGTR2 can be 
induced later in life under certain conditions, such as chronic heart failure [21]. It has 
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been shown that when Ang II binds to AGTR2, it activates tyrosine and serine/threonine 
phosphates which inhibits some of the AGTR1 pathways [21]. It also has been found that 
AGTR2 can cause hypertrophy in cardiomyocytes independent of Ang II [21]. The role 
of AGTR2 must be examined more closely because its functions are not fully understood 
at this time [21].  
1.4 PRESTO-TANGO System  
 The human genome produces approximately 350 nonolfactory GPCRs, of which 
just over one third are orphan receptors, meaning that their ligands are unknown [26]. 
Unknown GPCRs are a major concern because GPCRs are important in the treatment of 
various diseases since they are a key target for current medications in the market, with 
30% to 40% targeting nonolfactory GPCRs [26- 28]. GPCRs are the primary target of 
many candidate drugs, but GPCRs can also be non-specifically targeted [28]. This poses 
a problem when designing medications specifically meant to target a specific GPCR 
because this might produce unwanted side effects [28]. Therefore, detecting and 
understanding GPCRs and ligand interaction are essential to prescribing current and 
future medications. However, the detection of GPCRs has been limited due to deficient 
detection methods.  
  Detection methods have involved chemical and physical approaches, but both 
have presented limitations [28]. Chemical detection of GPCRs has involved looking at 
interactions between small molecule and GPCRs, as well as larger scale detection 
methods such as chemical databases [28]. Using the information available in chemical 
databases about GPCRs allows predictions about targets to be made [28]. However, these 
methods can be time-consuming efforts that rely on accurate data to be entered [28]. 
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Physical detection has historically relied on radioligand detection, but this method has 
been limited by the number of labelled ligands [27, 28]. Other methods have involved G-
protein-dependent functional assays such as cAMP assay, IP3/IP1 and Ca
2+
 assay, GTPγS 
binding assay, and reporter assays [27].  
G-protein-dependent functional assays also can involve G-protein-mediated 
events [27]. Therefore, detection methods independent of the classical GPCR pathway 
are termed G-protein-independent functional assays [27]. The ability of most GPCRs to 
recruit β-arrestin is important because β-arrestin signalling and G-protein signalling are 
independent of classical G-protein signalling [28]. Although other assays use β-arrestin, 
the transcriptional activation following the arrestin translocation (TANGO) method has 
shown promising results [26, 28]. Therefore, it was expanded upon to create a parallel 
receptor-ome expression and screening via transcriptional output-transcriptional 
activation following arrestin translocation (PRESTO-TANGO) [26, 28].  
 PRESTO-TANGO is a new method developed by Dr. Bryan Roth and colleagues 
that expanded on the TANGO method, which is an efficient chemical integration method 
that permits the scanning of one target with one receptor at a time [26, 28]. This system 
allows the ligand and GPCR to be scanned without interference from other G-protein-
mediated factors [27, 28]. The PRESTO-TANGO method expands upon this system and 
allows multiple compounds to be scanned against the human genome at once [26]. The 
PRESTO-TANGO method, a cell culture-based system, facilitates the determination of 
agonists of GPCRs. The cells that are used in this model are a HTLA cell line, a 
derivative of the HEK293 cell line, which is capable of expressing tetracycline 
transactivator (tTA) luciferase -β-arrestin-2-Tobacco Etch Virus (TEV) fusion genome 
10 
 
[26]. For each GPCR, a TANGO construct was created, resulting in 315 constructs. 
However, not all constructs could be validated by agonists, even if they were nonorphans 
[26].  
 In general, the system works by a ligand binding to the GPCR, which has been 
transfected into the cell, and upon binding, the β-arrestin -2-TEV fusion protein is 
recruited [26]. The fusion protein is then cleaved, which facilitates the release of tTA 
[26]. The tTA then binds to the nucleus and activates the luciferase reporter gene [26]. 
The luminescence produced can then be measured (Figure 3) [26]. This system, through 
the activation of a receptor (by increased luminescence), allows for the determination of 
agonists of GPCRs (Figure 4). This is a revolutionary system because of its ability to scan 







a)   b)  
Figure 3. PRESTO-TANGO system. Adapted from  W. Kroeze et al. Nature Structural & 
Molecular Biology (2015) [26].  a) 1. Ligand binds to GPCR, 2. β-arrestin -2-TEV fusion 
protein is recruited to receptor, 3. fusion protein in then cleaved and tTA is released and 





Figure 4. Mechanism of PRESTO-TANGO system. Luminescence signal can be 




 Resveratrol (3,5,4′-trihydroxy-trans-stilbene), a polyphenol, is a naturally 





phenolic rings attached by a double bond (Figure 5) [31]. Resveratrol is present in two 
isomer formations, the cis- and trans- formation, with the trans-formation being the more 
stable of the two [31].  
 
a)  b)  
Figure 5. Molecular structure of resveratrol. Image from J. Gambini et al. Oxidative 




 Resveratrol is found in a variety of plants and many different foods [30, 31]. 
Specifically, some plants produce resveratrol in response to stress [30]. Common foods in 
which resveratrol is found include, grapes, blueberries, blackberries, and peanuts [29, 30, 
31]. However, based on the Mediterranean diet, resveratrol is consumed mostly through 
red wine [31]. The resveratrol present in wine comes from the grapes, with the skin, 
seeds, petioles, and woody parts being the most concentrated source [31]. A high 
concentration has been reported in the grape types of Vitis vinifera, labrusca, and 
muscadine at a concentration of 50 to 100 μg/g in skin and seeds [32]. The amount of 
resveratrol found in plants varies because of different conditions, such as environmental 
factors [31].  
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 Resveratrol has been studied for approximately 70 years but more so in the last 
decade. It has been reported  to have many beneficial effects, including antioxidant, 
anticancer, and anti-inflammatory properties [31]. Resveratrol offers a great range of 
potential health benefits, but it has been difficult to suggest a certain dosage for treatment 
or supplement [33]. Many studies have examined the benefits of resveratrol in vitro and 
in vivo using animal models, and even though research has been performed in human 
studies, research still has been lacking in clinical trials [31]. This is mainly due to the 
lacking information about the absorption and metabolism of resveratrol [33].  
Resveratrol’s efficiency is dependent on the way it is consumed [31]. Low 
bioavailability and the ways in which resveratrol’s metabolites are absorbed can affect its 
efficiency [31]. It has been suggested that metabolites such as glucuronides and sulfates, 
rather than free resveratrol, might be responsible for some of the benefits because they 
usually are detected in urine up to 9 hours after ingestion [33, 34]. The potential side 
effects of long-term use also are unknown at this time [33]. The reason this is important 
is because resveratrol can accumulate in tissue [33]. One study has estimated that on 
average, men consume 1629 μg/day and women consume 235 μg/day of resveratrol [33]. 
Concentrations at these amounts have shown no adverse side effects [33].  
 The bioavailability of resveratrol varies greatly, depending on the method of 
distribution (i.e., orally, infusion) [31]. Bioavailability of resveratrol using oral 
absorption has been reported at 75% [35]. However, a concern with oral absorption of 
resveratrol has been its low plasma concentration levels [31]. It also has been reported 
that the use of resveratrol might be limited because of poor absorption [31]. 
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  In animal studies, resveratrol has been found effective in reducing blood pressure 
in hypertensive rats and also working in combination with antihypertensive medication 
[36]. Resveratrol has been reported as lowering systolic blood pressure at a concentration 
of ≥ 150 mg/day [37]. However, in a meta-analysis combining six studies with 247 
participants, the compiled previously reported data indicated that resveratrol had no 
significant effect on systolic or diastolic blood pressure [37]. There have been limited 
studies regarding the antihypertensive role of  resveratrol treatment in clinical trials.  
1.6 Pterostilbene  
 Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene) is a derivative, a 
dimethylated form, of the polyphenol resveratrol [31, 38]. Although very similar in 
structure, it is believed that pterostilbene has better bioavailability because of the two 
methoxy groups [38]. The addition of the methoxy groups improves its lipophilic nature 






Figure 6. Molecular structure of pterostilbene and resveratrol. Image from D. 
McCormack & D. McFadden. Oxidative Medicine and Cellular Longevity (2013) [38]. 
Image (a) pterostilbene and (b) resveratrol [38]. 
 
 
 Pterostilbene sources are found in foods such as fruits, nuts, and plants [31, 38]. 
The most well-known source is blueberries, with an average of between 99 and 
520 ng/gram per berry [38]. Although it is considered concentrated in grapes, grapes 
contain smaller amounts of pterostilbene in comparison to resveratrol [39, 40]. Recent 
studies have reported  pterostilbene posses antioxidant capability and  has the ability to 
reduce oxidative stress [38, 39, 40]. Along with pterostilbene showing antioxidant 
capability, it has been shown to possess antiproliferative and anti-inflammatory abilities 
[38, 39]. It also has been shown that pterostilbene can inhibit apoptosis and autophagy 
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[38]. It has been found that pterostilbene has greater bioavailability in oral administration 
compared to resveratrol [38]. One animal study reported that pterostilbene had an 80% 
bioavailability compared to resveratrol at 20% [38, 41]. Again, more studies need to be 
conducted regarding resveratrol and pterostilbene pharmacokinetics.  
Pterostilbene is an understudied compound that needs to be examined more 
closely in a clinical setting, especially in regard to hypertension and associated 
cardiovascular complications. In particular, there has been limited research on this 
compound’s effect on blood pressure regulation. Evidence has shown that pterostilbene 
does lower blood pressure in adults with hypercholesterolemia [42]. The study, which 
was conducted in 2014, concluded that a higher dosage (250 mg/day) was effective in 
lowering blood preassure [42]. The safety of 250 mg/day also was studied, and it was 
reported to be generally safe [43]. However, more research is needed to investigate the 
role of pterostilbene in hypertensive patients.  
1.7. Rationale 
Ang II is associated with hypertension, and it is known to increase blood pressure 
when bound to AGTR1. Ang II will activate AGTR1 in the PRESTO-TANGO system 
because it is an agonist. Although resveratrol and pterostilbene in some cases have been 
reported to lower blood pressure, their  mechanisms of action are not well understood. 
This study sought to determine the effect of resveratrol and pterostilbene on AGTR1 
activation. Targeting AGTR1 will help to clarify the role of these ligands in hypertension. 
However, it must be noted that before resveratrol and pterostilbene effects can be 
determined on AGTR1 activation the PRESTO-TANGO system must be optimized for 
the study. The PRESTO-TANGO system has not been used to study the effects of these 
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compounds on AGTR1 activation before. Therefore many aspects of this system must be 
optimized such as AGTR1 concentration, the effect of time on the system, treatment 
concentrations and cell densities. Until the system is optimized the effect of resveratrol 
and pterostilbene on AGTR1 activation cannot be determined.  
1.8 Hypothesis 
 In the presence of Ang II, resveratrol and/or pterostilbene will prevent Ang II 
induced AGTR1 activation.  
1.9 Specific Aims  
1. Optimize the PRESTO-TANGO method with AGTR1 receptor.  
2. Determine the effect of resveratrol on AGTR1 using the optimized PRESTO-
TANGO method. 





Chapter 2: Methods 
2.1 Transformation of Competent Cells  
 Escherichia coli D5H-α competent cells (Fisher, NH, USA) were transformed 
using the plasmids AGTR1-Tango (Addgene, MA, USA cat. #66222) or pGL4.54 
[luc2/TK] Vector (Promega, WI, USA cat. #E5061). This was done by mixing 1μL of 
plasmid with 50 μL of competent cells. The mixture was then incubated on ice for 30 
minutes and then heat shocked for 1 minute at 43° C. To the plasmid and competent cell 
mixture, 400 μL of sterile LB Broth (Fisher, NH, USA) was added and then placed in  
a 37° C shaking incubator for 1 hour. The mixture was then spread at a volume of 50 μL 
on to LB agar plates containing 100 μg/mL of ampicillin because both vectors contained 
the ampicillin resistant gene. After allowing the plates to dry, they were placed in an 
incubator at 37° C, 5% CO2, and 100% humidity overnight.  
 The following day, colony growth was verified by examining a negative control 
containing only competent cells and no plasmid. A single colony was then added to a 
flask containing 100 mL of sterile LB Broth and 100 μg/mL of ampicillin. This protocol 
was always done in duplicates. Furthermore an extra mL was made of bacterial culture 
for the future storage of plasmids. The flasks were then placed in a 37° C shaking 
incubator and left overnight.  
 The following day, the extra 1 mL of bacterial culture was combined with 1 mL 
of 50% glycerol and stored at -80° C . Maxi preps were made with the remaining bacterial 
culture following the ZymoPure
TM 
Plasmid Maxiprep Kit (ZYMO RESEARCH, CA, 
USA cat.# D4202) manufacturing protocol. The eluted plasmids from the maxi preps 
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were stored at -20° C, and concentrations were read using a Take3™ microplate reader 
with Gen5 program (BioTek, VT, USA). 
2.2 Cell Culture Methods  
HTLA cells, a derivative of the HEK293 cell line, are capable of expressing 
tetracycline transactivator (tTA) luciferase -β-arrestin -2-Tobacco Etch Virus (TEV) 
fusion genome. The cells were obtained from the laboratory of Dr. Gilad Barnea. These 
cells were grown and cultured in 100 x 20 mm vacuum-glass plasma treatment tissue 
culture dishes (Corning, NY, USA). The cells were split at approximately 90% 
confluency and were seeded at 1,440,000 cells per plate. Cells were grown in a 
supplemented medium (10 mL per 100 x 20 mm) that consisted of Dulbecco’s Modified 
Eagles Medium (DMEM; Sigma-Aldrich, MO, USA); 10% fetal bovine serum (Hyclone, 
PA, USA); 1% antibiotic-antimycotic (Gibcco, CA, USA); 1% gentamicin (Gibcco, CA, 
USA); 0.2% hygromycin B (Fisher, NH, USA); and 0.05% puromycin (Gibcco, CA, 
USA). Cells were then incubated at 37° C, 5% CO2, and 100% humidity for all 
experiments, unless otherwise stated.  
2.3 Transfection 
 When cells were at approximately 60% confluency, the transfection mixture (300 
μL) was added to the cells. The transfection mixture consisted of DMEM; FuGENE 6 
(Promega, WI, USA); and the receptor plasmid AGTR1 (Addgene, MA, USA) at 0.1μg. 
FuGENE 6 to AGTR1 was added at a 60:1 ratio in DMEM. Control cells received 300 µl 
of DMEM only. All other wells received AGTR1 transfection mixture and  pGL4.54 had 
its own transfection  mixture substituted for AGTR1 using the same ratio. Cells were then 
incubated for 24 hours.   
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2.4 Treatment   
 After 23.5 hours of being transfected, the cells were split into six-well plates 
(Corning, NY, USA) with 400,000 cells/mL. Cells were grown in supplemented media at 
1 mL/well, along with the addition of 1 mL of corresponding treatment. Control cells and 
AGTR1 control cells not receiving specific treatment had 1 mL of supplemented media 
added. Cells were then incubated for 24 hours.  
2.4.1 Resveratrol Treatment  
 A 5-mM stock concentration of resveratrol was prepared by dissolving 0.028 g of 
resveratrol (Sigma-Aldrich, MO, USA) into 20 mL of distilled water. The concentrations 
of 50 μM, 100 μM, and 200 μM were made from resveratrol stock using supplemented 
media, and then 1 mL of resveratrol treatment was added to each well. Treated cells were 
then incubated for 24 hours. 
2.4.2 Ang II Treatment  
 A 32-mM stock concentration of Ang II was prepared by dissolving 0.005 g of 
Ang II (Sigma-Aldrich, MO, USA) into 15 mL of distilled water. A 43-nM concentration 
was made up from Ang II stock concentration using supplemented media, and then 1 mL 
of Ang II treatment was added to each well. Treated cells were then incubated for 24 
hours. 
2.4.3 Losartan Treatment  
 A 10-mM stock concentration of losartan was prepared by dissolving 0.072 g of 
losartan (Sigma-Aldrich, MO, USA) into 15 mL of distilled water. A 1333-nM 
concentration was made up from losartan stock concentration using supplemented media, 
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and then 1 mL of losartan treatment was added to each well. Treated cells were then 
incubated for 24 hours. 
2.4.4 Ang II + Losartan Treatment  
  A cotreatment mixture of 43 nM of Ang II and 1333 nM of losartan was prepared 
together using supplemented media, and then 1 mL of cotreatment was added to each 
well. Treated cells were then incubated for 24 hours. 
2.4.5 Ang II + Resveratrol Treatment  
Cotreatment mixtures of 43 nM of Ang II and 50 μM, 100 μM, and 200 μM of 
resveratrol was prepared together using supplemented media, and then 1 mL of 
cotreatment was added to each well. Treated cells were then incubated for 24 hours. 
2.4.6 Pterostilbene Treatment  
A 5-mM stock concentration of pterostilbene was prepared by dissolving 0.001 g 
of pterostilbene (Sigma-Aldrich, MO, USA) into 15 mL of dimethyl sulfoxide (DMSO). 
A 20-μM concentration was made up from the pterostilbene stock concentration using 
supplemented media, and then 1 mL of pterostilbene treatment was added to each well. 
Treated cells were then incubated for 24 hours. 
2.4.7 Ang II + Pterostilbene  
A cotreatment mixture of 43 nM of Ang II and 20 µM of pterostilbene was 
prepared together using supplemented media, and then 1 mL of cotreatment was added to 






2.5 Cell and Viability Test 
 Cell counts were performed when cells reached approximately 80% confluency 
(22 hours later). The media was then removed from the wells, and the cells were washed 
with 1 mL of phosphate buffered saline (PBS), and 500 µL of trypsin was added. Cells 
were then incubated for 2 minutes at 37˚ C, 5% CO2, and 100% humidity. Once the cells 
were tryspinized, a 1:1 ration of Trypan Blue 0.4% (GE Healthcare, ON, Canada) was 
used. Cell counts were done using hemocytometer and 10x Nikon phase microscope in 
which live and dead cells were counted. Trypan Blue enters only nonviable cells, thus 
facilitating the detection of dead cells via the blue stained cells.  
2.6 Reading Luminescence (Bright-Glo™ Luciferase Assay System)  
Luminescence readings were taken 24 hours after treatment was added. Media 
were removed from the wells, and then 100 μL of Bright-Glo (Promega, WI, USA) was 
added to each well in the six-well plate. The six-well plate was then incubated for 5 
minutes on Belly Dancer (Stovall, NC, USA) in the dark. After 5 minutes, the 100 µL in 
each well was transferred to a corresponding well on a white half area 96-well plate 
(Corning NY, USA). Using the FLUOstar OPTIMA (BMG LABTECH, Germany), 
luminescence readings were taken using the setting of 1 cycle with an interval 
measurement time of 4.06 seconds and a cycle time of 10 seconds, along with a wait time 
of 5 minutes prior to reading.  
2.7 BrdU Fixing and Reading   
 When the HTLA cells were at approximately 70% confluency, the cells were 
treated with 1mM Bromodeoxyuridine (BrdU) and  were incubated for 30 minutes. 
Media were removed, and the cells were washed with PBS (10 mL) and trypsinized (2 
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mL). Cells were then incubated for 5 minutes. Supplemented media (4 mL) were then 
added, and cell suspension was transferred to centrifuge tubes. The tubes were then spun 
at 500 x g for 5 minutes at 22° C. Supernatant was then removed, and the pellet was 
suspended in 200 μL of PBS. Cells were then fixed in chilled 70% ethanol, with ethanol 
being added dropwise while the centrifuge tube was being vortexed. Fixed cells were 
then stored in 4° C up to a week.   
 Cells were spun at 200 xg for 15 min at 22° C in centrifuge (Beckman Coulter, 
CA, USA). Pre-coating of microcentrifuge tubes was completed with a 0.1% bovine 
serum albumin-phosphate buffered saline (BSA-PBS). BSA-PBS at 1 mL was added to 
each microcentrifuge tube. Supernatant of BrdU was discarded, as was the BSA-PBS 
solution. To the precoated tube with pellet 670 μL of distilled water and 330 μL of 6M, 
hydrochloric acid was then added. Microcentrifuge tubes were then vortexed and 
incubated for 30 minutes at room temperature. Microcentrifuge tubes had 0.1M Borate 
Buffer added. Cells were spun at 200 x g for 15 minutes at 22° C in centrifuge. 
Supernatant was then discarded. Microcentrifuge tubes had 0.1M Borate Buffer B added. 
Cells were then spun at 200 x g for 5 minutes at 22° C in centrifuges. Supernatant was 
then discarded. Microcentrifuge tubes had 1 mL of BSA-PBS added. Cells were then 
spun at 200 x g for 5 minutes at 22° C in centrifuge. A anti-BrdU solution was made up 
with a 5 μL/100 μL of 0.1% BSA-PBS. Supernatant was then discarded. Each sample 
then had 50 μL of anti-BrdU/BSA-PBS added to it and was resuspended until no particle 
matter was visible. Microcentrifuge tubes were then incubated for 30 minutes in the dark; 





 The optimized data presented corresponds to four (n = 4) independent 
experiments, and all statistical analyses were performed using GraphPad Prism 5 
software. Data was presented as mean ± standard error of the mean (SEM). All data used 























Chapter 3: Results 
3.1. Results of Optimization  
  Before the effect of resveratrol and pterostilbene on AGTR1 activation could be 
determined, the system had to be optimized. The PRESTO-TANGO system presents 
great potential for understanding the GPCR-ligand interaction, but because it is a new 
method, limited information is available. This study was the first time that AGTR1 had 
been examined with the compounds resveratrol and pterostilbene. As there has been no 
literature on this current method with these compounds, many steps in the procedure had 
to be optimized. This included AGTR1 itself, especially in regard to luminescence 
readings, time, treatments, and cell densities. Figure 7 displays the optimization steps that 
were taken to optimize the system. Section 3.1 includes a detailed discussion of these 
areas of optimization.  
 
 
Figure 7.  Optimization steps. Chart displays the major areas of AGTR1 luminescence 
reading, time, treatment and cell densities that needed to be optimized and the steps that 




AGTR1 displays an increased activation in the PREST0-TANGO system 
 To test the system, HTLA cells were grown to approximately 90% confluency 
and then split into six-well plates. Cells were plated at a volume of 200 μL into 2 mL of 
supplemented media (Day 0). After 24 hours of cells being incubated (Day 1), they were 
transfected with a 6:1 ratio of FuGENE 6 and AGTR1 plasmid, with the exception of the 
control. After being incubated for another 24 hours (Day 2), the media was removed, and 
cells were treated with resveratrol at the concentrations of 50 μM, 100 μM, 200 μM, and 
400μM or supplemented media. After being incubated for another 24 hours (Day 3), 
luminescence readings were taken. Luminescence reading are reported  in relative light 
units (RLU). The average readings indicated that AGTR1 activation was approximately 
40 times higher than the control (nontransfected cells) at a luminescence reading of 
404,653.5 to 14,872 (Figure 8). Bright-Glo reagent and supplemented media alone had 
luminescence readings similar to the average blank (empty well; Figure 8). Average 
resveratrol treated cells showed an increase in luminescence reading with 50 μM at 
440,473, 100 μM at 460,092 and 200 μM at 470,929 , except 400 μM of resveratrol 
caused a decrease in luminescence at a value of 196,763 (Figure 8). Based on the 
luminescence readings, these results showed that AGTR1 was being activated compared 
to the control. If AGTR1 was being activated, it was difficult to state the effect of 
resveratrol on the receptor.  
 To test the system, another trial was performed, except on Day 2, when cells were 
treated with the AGTR1 antagonist losartan (1333 nM). Average luminescence readings 
indicated that AGTR1 was significantly larger than the control alone at a reading of 
999,013.5 to 21,966.5, but losartan reduced the luminescence reading (Figure 9). This 
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system reports the agonist’s affect, this trial showed that losartan did not have an agonist 
effect on AGTR1 because it had a lower reading than that of AGTR1 alone. However, 
AGTR1 was still high compared to the control, and this experiment indicated that the 
system was working correctly with the antagonist. This finding suggests that AGTR1 was 
being activated by a possible ingredient in the media.  
Reduced percentage of FBS lowers AGTR1 activation but reduces cell density.  
 Looking at the media alone, it was thought that testing different amounts of FBS 
might have lowered AGTR1 luminescence readings because FBS can contain unknown 
ingredients. The experiment was carried out as previously stated, except the cells were 
grown in supplemented media with decreasing amounts of FBS (10%, 5%, 2.5%, and 
0%). Control had an average luminescence reading of 21,439 (Figure 10). As the 
percentage of FBS in supplemented media decreased, the average luminescence readings 
showed a decrease in AGTR1 activation with values of 1,846,472 for 10% FBS, 410,442 
for 5% FBS, 247,177 for 2.5% FBS, and 46,939 for 0% FBS (Figure 10).   
 Another dilution FBS trial was performed using 10%, 5%, and 2.5% FBS in the 
supplemented media under the same conditions, and nontransfected cells also were 
assessed with the same dilutions of FBS. Reducing the amount of FBS in the 
supplemented media also showed a decrease in luminescence of cells transfected with 
AGTR1 because 10% FBS had a 3,975,003 average luminescence and 5% FBS had a 
453,011 average luminescence (Figure 11). The exception was 2.5%, which had a 
586,425 average luminescence (Figure 11). Control cells with different amounts of FBS 
in supplemented media showed similar average luminescence’s (Figure 11). Based on 
this information  it was obvious that reducing the %  of  FBS in media reduced  the 
28 
 
AGTR1 activation, but it was unclear if the reduced nutrients were the reason for limiting 
cell growth.  
 Reducing the FBS might also have been limiting cell growth; therefore, another 
trial was performed under the same conditions, except 10% FBS was filter sterilized. To 
filter out small compounds from 10% FBS, it was thought that AGTR1 levels could be 
reduced without effecting the nutrient concentrations greatly. Control, 10% FBS, 10% 
filter sterilized FBS and 0% FBS conditions were examined under previous conditions. 
The control had a luminescence reading of 9,902 (Figure 12). AGTR1 transfected cells 
grown in 10% FBS-supplemented media had a luminescence reading of 730,836, 10% 
filter sterilized FBS-supplemented media had an increased luminescence reading of 
857,875 and 0% FBS supplemented media had a decreased luminescence reading of 
32,603 in regards to AGTR1 10% FBS (Figure 12). These results indicated that filter 
sterilizing FBS had no effect on AGTR1 luminescence readings.  
  To confirm the observation that reducing FBS caused a decrease in cells by Day 
3, cell counts and viability tests were performed on Day 3 under the same conditions. As 
shown in Table 1, cell counts indicated a decrease in cell density with decreasing 
amounts of FBS in supplemented media, and cell viability remained consistent. This 
result confirmed that lowering the amounts of FBS reduced the number of cells, which 
might have affected the results of the treatment on the receptor activation.  
 Another trial was performed under the same conditions, except dialyzed 10% FBS 
in the supplemented media was examined by removing activating compounds from the 
FBS and maintaining nutrients. Control and AGTR1 were performed under the same 
conditions, except on Day 0, 250,000 cells/well at a volume of 2 mL were seeded, as 
29 
 
opposed to the volume of 200 μL into the six-well plates. Control had an average 
luminescence reading of 28,053.5, and AGTR1-transfected cells grown in 10% dialyzed 
FBS-supplemented media had an average luminescence reading of 2,453,582 (Figure 13). 
Indicating again AGTR1 was still being activated when compared to the control.  
AGTR1 plasmid amount reduction reduces AGTR1 activation 
 Previous trials had used 1 μg of AGTR1 in transfection. To determine if the 
amount of AGTR1 had an effect on the increased luminescence values compared to the 
control, the AGTR1 concentrations of 0.03 μg, 0.05 μg, 0.07 μg, 0.1 μg, and 0.12 μg 
were examined. HTLA cells were grown to approximately a  90% confluency and then 
split into six-well plates (Day 0). Cells were plated at a volume of 200 μL into 2 mL of 
supplemented media. After 24 hours of cells being incubated, they were transfected with 
an increasing ratio of FuGENE 6 to AGTR1 plasmid, with the exception of the control. 
After being incubated for 24 hours (Day 2), media were removed, and cells were treated 
with supplemented media. After being incubated for another 24 hours (Day 3), 
luminescence readings were taken, with a wait time of 15 minutes before reading. 
Luminescence readings showed an increase in AGTR1 activation when the amount of 
AGTR1 and FuGENE 6 increased, except for 0.05 and 0.07 μg (Figure 14). AGTR1 0.03 
μg had a luminescence reading of 91,372 , 0.05 μg had a luminescence reading of 63,957, 
0.07 μg had a luminescence reading of 90,297, 0.1 μg had a luminescence reading of 
128,747, and 0.12 μg had a luminescence reading of 160,564 (Figure 14). From the data 





Time does not significantly alter luminescence readings  
 To examine the effect of time on luminescence readings, the trial examining the 
effect of AGTR1 plasmid reduction (Figure 14) also was run over a course of 10 minutes. 
Luminescence values were read using the FLUOstar OPTIMA, for 20 cycles with cycle 
time of 30 seconds and a measurement interval time of 1 second. Figure 15a displays all 
20 readings over the course of 10 minutes for each sample. Control showed a decrease 
over 10 minutes, as did all AGTR1 plasmid amounts. Blanks remained consistent over 
the 10 minutes. The average luminescence values over the 10 minutes were graphed for 
each sample (Figure 15b). These results indicated that a snapshot reading, which is a 1-
point reading, is still an accurate form of measurement as the values over 10 minutes 
gradually decrease.  
  The other factor that could have been influenced  the reading was the duration  of 
the cell treatment. To examine the effect of time on the PRESTO-TANGO system with 
respect to treatment time, the effect of the agonist Ang II was examined. Following the 
information obtained thus far and until stated otherwise, HTLA cells were grown to 
approximately 90% confluency and then split into six-well plates (Day 0). Cells were 
plated at 250,000 cells/well at a volume of 2 mL of supplemented media. After 24 hours 
of cells being incubated, they were transfected with a 60:1 ratio of FuGENE 6 to AGTR1 
plasmid (0.1 μg), with the exception of the control. After being incubated for 24 hours 
(Day 2), the media were removed, and cells were treated with supplemented media and 
Ang II. After being incubated for another 24 hours (Day 3).  Luminescence readings 
showed a minor increase in readings, with a trend for increasing signal with increasing 
duration of AngII exposure, with the exception of Ang II at 36 hours (Figure 16). This 
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showed that the agonist worked because it was almost double that of AGTR1, indicating 
activation of receptor. It also demonstrated that time did not have a significant influence 
on luminescence readings. 
The effect of Ang II and losartan on AGRTR1 and cell viability  
  The effect of the concentrations of 43 nM Ang II and 1333 nM losartan on cell 
viability and AGTR1 activation was examined. Methods were followed as previously 
stated, except on Day 2, cells were treated with supplemented media, Ang II, losartan, 
and Ang II + losartan (all treatments treated with AGTR1). After being incubated for 
another 24 hours, luminescence readings were taken, with a wait time of 15 minutes 
before readings. Average luminescence readings indicated that AGTR1 was slightly 
increased above control, Ang II caused an increased luminescence, losartan had a 
decreased luminescence, and Ang II + losartan had a decreased average luminescence 
with respect to AGTR1 (Figure 17). Cell density and viability of cells were calculated for 
Ang II and losartan. As shown in Table 2, Ang II and losartan both had a high cell 
viability. As these concentrations produced the expected agonist and antagonist effect 
(Ang II has an increased signal, and losartan has a decreased signal) and had high 
viability, these concentrations were selected for the remainder of the experiments. 
The effect of resveratrol on cell viability  
The effect of the concentrations 50 μM, 100 μM, 200 μM, and 400 μM of 
resveratrol on cell viability and AGTR1 activation was examined. Methods were 
followed as previously stated, except on Day 2, cells were treated with supplemented 
media, Ang II, resveratrol 50 μM, 100 μM, 200 μM and 400 μM (all treatments in the 
presence of AGTR1). Average luminescence readings indicated that AGTR1 was higher 
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than control. Ang II had a large increase with respect to AGTR1. Resveratrol 50 μM had 
a decreased average luminescence compared to AGTR1; resveratrol 100 μM and 200 μM 
had an increase (Figure 18). All of the resveratrol concentrations plus Ang II had an 
increased average luminescence over AGTR1, with resveratrol 50 μM having the largest 
increase and then descending with increasing concentration (Figure 18). Cell density and 
viability of cells were calculated for all controls and treatments, as shown Table 3. 
Although viability was high for all conditions, confluency was decreasing with treatment 
conditions compared to control and AGTR1.  
Efect of pterostilbene on AGTR1 activation and cell viability  
  The effect of the concentrations 20 μM, 40 μM, 60 μM and 100 μM pterostilbene 
on cell viability and AGTR1 activation was examined. Methods were followed as 
previously stated, except on Day 2, cells were treated with supplemented media and 
pterostilbene (all treatments treated with AGTR1). Average luminescence readings 
indicated that AGTR1 had a higher luminescence then the control (Figure 19). 
Pterostilbene had an increased average luminescence reading when increasing 
concentrations, except for 100 μM pterostilbene, which had a reading close to control 
(Figure 19), although 20 μM, 40 μM, 60 μM had a similar reading to AGTR1. Cell 
density and viability of cells were calculated for all controls and treatments, as shown in 
Table 4. Although the viability was higher than 87% for all groups’ cell densities were 
decreasing with higher concentrations of treatment conditions compared to control and 
AGTR1. 
 Another trial was performed to look at the effect of the concentration of 20 μM in 
the PRESTO-TANGO system. Pterostilbene 20 μM was chosen because it had the 
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highest cell density (Table 4). Following the above conditions, the experiment was 
repeated with control, AGTR1, Ang II, losartan , pterostilbene, and pterostilbene + Ang 
II. Control had an average luminescence of 46,419; AGTR1 had a similar average 
luminescence of 59,165 (Figure 20). Ang II had an increased average luminescence of 
161,140 (Figure 20). Pterostilbene had an increased average luminescence over control 
and AGTR1 at 97,248 (Figure 20). Pterostilbene + Ang II had the highest increased 
average luminescence of 392,321 (Figure 20). Cell density and viability also were 
calculated, as shown in Table 5. Although the viability was greater than 95% for all 
conditions , treatment groups had a decreased cell density compared to that of control and 
AGTR1.  
Optimization of cell densities with treatments 
 To investigate the decreasing cell densities of treatment groups further cell 
proliferation also was measured using the BrdU assay (Appendix). These results showed 
that the treatment groups had a higher proliferation rate than that of the control. For this 
reason, to determine if cell counts would match proliferation rates on Day 3, the 
experiment was changed to match BrdU methods. HTLA cells were grown to 
approximately 90% confluency and then split into 100 x20 mm tissue culture dishes (Day 
0). Cells were plated at a volume of 1,440,000 cells/plate into a volume of supplemented 
media. After 24 hours of cells being incubated (Day 1), they were transfected with a 60:1 
ratio of FuGENE 6 to AGTR1 plasmid (0.5 μg). After being incubated for 24 hours (Day 
2), cells were split and plated into six-well plates at a volume of 250,000 cells/well in 
supplemented media and various treatments. Cells were split between Day 2 and Day 3 
so that the cells would reach 70% confluency by Day 3 instead of 90% to match BrdU 
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results. After being incubated for another 24 hours (Day 3), luminescence readings were 
taken. However, results could not be obtained because not enough cells grew to run in the 
machine (error occurred). 
 To obtain a large enough confluency of cells by Day 3, a variety of cell seedings 
were performed to determine what volume of cells allowed for an 80% confluency in a 
six-well plate. The number of 400,000 cells/well showed an 80% confluency after 24 
hours later. This experiment was performed again plating a volume of 400,000 cells/well 
between Day 2 and Day 3 (Figure 21). To examine this method with an 80% confluency 
control, AGTR1, Ang II, resveratrol 100 μM, resveratrol 100 μM + Ang II, and losartan 
groups were examined. Average luminescence for control had a value of 13,002; AGTR1 
had an increased value of 57,624 (Figure 21). Ang II had an increased average 
luminescence reading  as did resveratrol 100 μM (Figure 21). The highest increased 
average luminescence was resveratrol + Ang II  (Figure 21). Losartan showed a 
decreased average luminescence to AGTR1 (Figure 21). As shown in Table 6, all cell 









Figure 8. Effect of resveratrol on AGTR1 activation. Luminescence readings of control, 
1μg of AGTR1, 50 μM, 100 μM, 200 μM, and 400 μM of resveratrol treatments with 
AGTR1, supplemented media, Bright-Glo, and Blank. Cells were seeded at a volume of 
200 μL/well in six-well plates. Luminescence values were read using the FLUOstar 
OPTIMA one cycle with cycle time of 1 sec and a measurement interval time of 4.06 sec.  





























Figure 9. Effect of losartan on AGTR1 activation. Average luminescence readings of 
control, 1 μg of AGTR1, losartan (1333 nM) with AGTR1, and blank. Cells were seeded 
at a volume of 200 μL/well in six-well plates. Luminescence values were read using the 
FLUOstar OPTIMA one cycle with cycle time of 1 sec and a measurement interval time 

























Figure 10. Effect of FBS on AGTR1 activation. Average luminescence readings of 
control and 1 μg of AGTR1 with FBS dilutions in supplemented media and blank. Cells 
were seeded at a volume of 200 μL/well in six-well plates. Luminescence values were 
read using the FLUOstar OPTIMA one cycle with cycle time of 1 sec and a measurement 
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Figure 11. Effect of FBS on AGTR1 activation and control cells. Average luminescence 
readings of controls with 10%, 5%, and 2.5% FBS in supplemented media, 1 μg AGTR1 
with FBS dilutions of 10%, 5%, and 2.5% in supplemented media. Cells were seeded at a 
volume of 200 μL/well in six-well plates. Luminescence values were read using the 
FLUOstar OPTIMA one cycle with cycle time of 1 sec and a measurement interval time 

























Figure 12. Effect of FBS, filter sterilized FBS, and no FBS on AGTR1 activation. 
Luminescence readings of control, 1 μg AGTR1 with FBS dilutions of 10%, filtered 10% 
and 0% supplemented media, and blank. Cells were seeded at a volume of 200 μL/well in 
six- well plates. Luminescence values were read using the FLUOstar OPTIMA one cycle 
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Table 1. Cell Density and Viability 1. Number (#) of average viable, nonviable, and 
combined cells (average # of cells) per square for 10% FBS with AGTR1, 10% FBS filter 
sterilized with AGTR1, 5% FBS with AGTR1, 2.5% FBS with AGTR1, and 0% FBS 














Figure 13. Effect of dialyzed FBS on AGTR1 activation. Average luminescence reading 
of control, AGTR1, and blank made with 10% dialyzed FBS in supplemented media. 
Cells were seeded at 250,000 cells/well in six-well plates. Luminescence values were 
read using the FLUOstar OPTIMA, one cycle with cycle time of 1 sec and a 


























Figure 14. Effect of varying concentrations of AGTR1 plasmids. Luminescence readings 
of control, AGTR1 concentrations of 0.3 μg, 0.5 μg, 0.07 μg, 0.1 μg, 0.12 μg, and blanks. 
Cells were seeded at a volume of 200 μL/well in six-well plates. Luminescence values 
were read using the FLUOstar OPTIMA, for 1 cycle with cycle time of 1 sec and a 







































b)     
Figure 15. AGTR1 luminescence over time. Luminescence reading of control, AGTR1 
concentrations of 0.3 μg, 0.5 μg, 0.07 μg, 0.1 μg, 0.12μg, and blank. Cells were seeded at 
a volume of 200 μL/well in six-well plates. When cells were at ~60% confluency, they 
were transfected with FuGENE 6 for 24 hr in incubator. Supplemented media were 
changed, and plate was incubated for another 24 hr. Luminescence values were read 
using the FLUOstar OPTIMA for 20 cycles with cycle time of 30 sec and a measurement 
interval time of 1 sec. n = 1. a) luminescence over 20 cycles b) average luminescence 

















































Figure 16. Ang II luminescence over time. Average luminescence reading of control, 0.1 
μg of AGTR1, Ang II 6-, 12-, 24-, and 36-hr treatment periods with AGTR1 and blank. 
Cells were seeded with 250,000 cells/well in six-well plates. Luminescence values were 
read using the FLUOstar OPTIMA, for 1 cycle with cycle time of 1 sec and a 
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Figure 17. Effect of losartan in the presence of Ang II on AGTR1 activation. Average 
luminescence of control, 0.1 μg of AGTR1, Ang II (43 nM) with AGTR1, losartan (1333 
nM) with AGTR1, Ang II + losartan with AGTR1, and blank. Cells were seeded with 
250,000 cells/well in six-well plates. Luminescence values were read using the FLUOstar 
OPTIMA, for 1 cycle with cycle time of 1 sec and a measurement interval time of 4.06 































Table 2. Cell Density and Viability 2. Number (#) of average viable, nonviable, and 
combined cells (average # of cells) per square for Ang II with AGTR1 and losartan with 










Figure 18. Effect of resveratrol in the presence of Ang II on AGTR1 activation. Cells 
were seeded with 250,000 cells/well in six-well plates  Average luminescence reading of 
control, 0.1 μg of AGTR1,  Ang II (43 nM) with AGTR1, 50 μM, 100 μM, and 200 μM 
resveratrol treatments with AGTR1, 50 μM, 100 μM, 200 μM resveratrol treatments + 
Ang II. Luminescence values were read using the FLUOstar OPTIMA 1 cycle with cycle 
time of 1 sec and a measurement interval time of 4.06 sec.  





















Table 3. Cell Density and Viability 3. Number (#) of average viable, non-viable and 
combined cells (average # of cells) per square for control, AGTR1, Ang II with AGTR1, 
resveratrol 50 μM,100 μM, and 200 μM with AGTR1. Calculated cell density and cell 











       
 
 Figure 19. Effect of varying concentrations of pterostilbene on AGTR1 activation. 
Average luminescence reading of control, 0.1 μg of AGTR1, 20 μM, 40 μM, 60 μM, and 
100 μM pterostilbene treatments with AGTR1, and blank. Cells were seeded with 
250,000 cells/well in six-well plates. Luminescence values were read using the FLUOstar 
OPTIMA, for one cycle with cycle time of 1 sec and a measurement interval time of 4.06 






Table 4. Cell Density and Viability 4. Number (#) of average viable, nonviable,and 
combined cells (average # of cells) per square for AGTR1, Ang II with AGTR1,                    
pterostilbene 20 μM, 40 μM, 60 μM, and 100 μM with AGTR1. Calculated cell density 
















Figure 20. Effect of 20 μM pterostilbene in the presence of Ang II on AGTR1 activation. 
Average luminescence reading of control, 0.1 μg of AGTR1, Ang II (43 nM) with 
AGTR1, 20 μM pterostilbene treatment with AGTR1, 20 μM pterostilbene treatment + 
Ang II with AGTR1, and Blank. Cells were seeded with 250,000 cells/well in six-well 
plates. Luminescence values were read using the FLUOstar OPTIMA, for one cycle with 
























Table 5. Cell Density and Viability 5. Number (#) of average viable, nonviable, and 
combined cells (average # of cells) per square for control, AGTR1, Ang II (43 nM) with 
AGTR1, pterostilbene 20 μM and 100 μM with AGTR1. Calculated cell density and cell 
















Figure 21. Effect of resveratrol 100 μM in the presence of Ang II on AGTR1 activation. 
Cells were seeded with 400,000 cells/well in six-well plates Average luminescence 
reading of control, 0.1 μg of AGTR1, Ang II (43 nM) with AGTR1, 100 µM resveratrol 
with AGTR1, 100 µM resveratrol + Ang II with AGTR1, and blank. Luminescence 
values were read using the FLUOstar, for one cycle with cycle time of 1 sec and a 
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Table 6. Cell Density and Viability 6. Number (#) of average viable, nonviable, and 
combined cells (average # of cells) per square for control, AGTR1, Ang II (43 nM) with 
AGTR1, resveratrol 100 μM with AGTR1, Ang II + 100 μM with AGTR1 and losartan 
(1333 nM) with AGTR1. Calculated cell density and cell viability included. See appendix 














Figure 22. Effect of varying concentrations of pGL4.54 on AGTR1activation. 
Luminescence reading of control, pGL4.54 concentrations of 0.3 μg, 0.5 μg, 0.07 μg, 0.1 
μg, 0.12 μg, and blanks. Cells were seeded at a volume of 200 μL in six-well plates. 
Luminescence values were read using the FLUOstar OPTIMA, for one cycle with cycle 
































3.2. Optimized Results  
The effect of resveratrol and pterostilbene on AGTR1 activation  
 In the previous optimization steps, treatment groups had similar cell densities as 
control and AGTR1 groups. Therefore, optimized steps, as indicated in the Methods 
section, included using 10% FBS containing media, using a AGTR1 plasmid 
concentration of 0.1 μg, splitting cells between Day 2 and Day 3 for optimal confluency, 
and taking a snapshot luminescence reading. Trials were performed using the groups that 
included control, AGTR1, Ang II, losartan, resveratrol 50 μM, resveratrol 100 μM, 
resveratrol 200 μM, resveratrol 50 μM + Ang II, resveratrol 100 μM + Ang II, resveratrol 
200 μM + Ang II, pterostilbene 20 μM and pterostilbene 20 μM. In addition to treatment 
groups, pGL4.54, a control plasmid that was constantly expressed using Bright-Glo, was 
included. Before running the optimized trials, pGL4.54 was examined in the system with 
the different amount of 0.03 μg, 0.05 μg, 0.07 μg, 0.1 μg, and 0.12 μg. Control had a 
luminescence of 939 (Figure 22). The luminescence increased with an increase in 
pGL4.54 concentration as based on the following luminescence values of 0.03 μg at 
5,513, 0.05 μg at 7,393, 0.07 μg at 26,695, 0.1 μg at 40,450, and 0.12 μg at 263 (Figure 
22). Based on the numbers provided and the average luminescence of AGTR1, 0.1 μg of 
pGL4.54 was selected for the following optimized trials. Due to the ability of  pGL4.54 
to be constantly expressed, it acted as a parallel control by allowing luminescence 
readings to be standardizied against it.  
 The optimized trials were performed as described in the Methods section. The 
trials were performed four times , with each condition in a trial being performed in 
triplicate. Cell counts were taken 2 hours prior to the luminescence reading. As showing 
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in Tables 7, 8, 9 and 10, cell counts were all in close proximity to each other. However, 
the results were not statistically significant. As shown in Figure 23, the trends indicated 
that there was an increase luminescence in AGTR1 (0.73) from control (0.07). The 
treatment groups, in comparison to AGTR1, showed an increase with Ang II (1.09), a 
decrease with losartan (0.23), and a decrease with Ang II + losartan (0.21).  Resveratrol 
groups of 50 μM (0.92), 100 μM (0.94), and 200 μM (1.2) showed an increase above 
AGTR1, with 200 μM being slightly higher than others. Resveratrol 50 μM (1.27), 100 
μM (1.36) and 200 μM (1.05) + Ang II groups showed an increase above AGTR1 and 
showed a higher average luminescence than that of resveratrol groups, with the exception 
of resveratrol 200 μM + Ang II.  Pterostilbene 20 μM (0.75) had remained similar to 
AGTR1. With the addition of Ang II, it had the large increase above AGTR1 (1.28).  Ang 














Table 7. Cell Density and Viability Trial 1. Number (#) of average viable, non,viable, and 
combined cells (average # of cells) per square for control, AGTR1, pGL4.54, Ang II (43 
nM) with AGTR1, losartan (1333 nM) with AGTR1, Ang II + losartan with AGTR1, 
resveratrol 50 μM, 100 μM, 200 μM with AGTR1, Ang II + resveratrol 50 μM,100 μM, 
200 μM with AGTR1, pterostilbene 20 μM with AGTR1 and Ang II + pterostilbene 20 










Table 8. Cell Density and Viability Trial 2. Number (#) of average viable, nonviable, and 
combined cells (average # of cells) per square for control, AGTR1, pGL4.54, Ang II (43 
nM) with AGTR1, losartan (133 3nM) with AGTR1, Ang II + losartan with AGTR1, 
resveratrol 50 μM, 100 μM, 200 μM with AGTR1, Ang II + resveratrol 50 μM,100 μM, 
200 μM with AGTR1, pterostilbene 20 μM with AGTR1 and Ang II + pterostilbene 20 










Table 9. Cell Density and Viability Trial 3. Number (#) of average viable, non,viable, and 
combined cells (average # of cells) per square for control, AGTR1, pGL4.54, Ang II (43 
nM) with AGTR1, losartan (1333 nM) with AGTR1, Ang II + losartan with AGTR1, 
resveratrol 50 μM,100 μM, 200 μM with AGTR1, Ang II + resveratrol 50 μM,100 μM, 
200 μM with AGTR1, pterostilbene 20 μM with AGTR1 and Ang II + pterostilbene 20 











Table 10. Cell Density and Viability Trial 4. Number (#) of average viable, nonviable, 
and combined cells (average # of cells) per square for control, AGTR1, pGL4.54, Ang II 
(43 nM) with AGTR1, losartan (1333 nM) with AGTR1, Ang II + losartan with AGTR1, 
resveratrol 50 μM, 100 μM, 200 μM with AGTR1, Ang II + resveratrol 50 μM,100 μM, 
200 μM with AGTR1, pterostilbene 20 μM with AGTR1 and Ang II + pterostilbene 20 

































































































































































      
Figure 23. Effect of resveratrol and pterostilbene on AGTR1 activation. Average 
luminescence reading standardized to pGL4.54 of 0.1 μg AGTR1, Ang II, 50 μM, 100 
μM, 200 μM resveratrol treatments with AGTR1, Ang II + resveratrol 50 μM, 100 μM, 
200 μM with AGTR1, pterostilbene 20 μM with AGTR1 and Ang II + pterostilbene 20 












Chapter 4: Discussion 
Hypertension is mediated through the RAAS pathway [1]. The RAAS, through a 
variety of other systems, allows blood pressure homeostasis to be controlled [15]. Ang II, 
the major product of the pathway, works through two GPCRs, namely, AGTR1 and 
AGTR2 [44]. Ang II acts as an agonist to AGTR1, promoting vasoconstriction which 
allows for increased blood pressure [44].  
One of the major antihypertensive medications that target the RAAS is the Ang 
receptor blockers, which block the binding of Ang II [10]. Losartan is an Ang II blocker 
that acts as an antagonist to AGTR1 [44]. Losartan limits the binding of Ang II to 
AGTR1, allowing for a decrease in blood pressure [44]. Although medications are 
available some drugs can cause unwanted side effects and might not fully block [5, 10, 
11]. Therefore, naturally occurring compounds were studied as an alternative 
Two naturally occurring compounds belonging to the polyphenol family thought 
to reduce blood pressure are resveratrol and pterostilbene [36, 38, 42]. Resveratrol in 
clinical and animal studies has been shown to reduce blood pressure [36]. Pterostilbene is 
an understudied compound in the cardiovascular system, with only one study showing 
that pterostilbene supplements can reduce the blood pressure of patients with high 
cholesterol [42].  It is thought that pterostilbene has better bioavailability because of the 
slightly altered structure from resveratrol but also might have a more toxic effect [38]. 
Although both compounds have the ability to lower blood pressure, neither compound 
had been examined specifically for its effect on the AGTR1 receptor. In fact, resveratrol 
and pterostilbene have yet to be studied at the receptor level regarding hypertension 
because interactions between GPCRs and ligands are not easily detectable.  
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 The PRESTO-TANGO method developed by the Bryan Roth lab group is a 
revolutionary system that eased the detection of receptor and ligand activation without 
interference [26]. The most promising aspect of this system is that it facilitated the 
scanning of the entire human genome with a compound/ligand at once, allowing new 
activities of GPCRs to be determined. Constructs of GPCRs were designed specifically 
for this system, including AGTR1. This system allowed researchers to study the effect of 
these polyphenols role in hypertension by looking at their effect on AGTR1 activation.  
The PRESTO-TANGO system, although a revolutionary system for studying 
GPCRs and ligand interaction, was still a new system. This meant that the PRESTO-
TANGO system had to be optimized to look at AGTR1 with the compounds of 
resveratrol and pterostilbene. Currently, limited methods are available for this system, but 
they have never been optimized specifically for AGTR1. To optimize this study, the 
limited amount of available information on the PRESTO-TANGO was combined with 
knowledge from the TANGO method [26, 45].  
4.1 Optimization of System  
The system first had to be investigated to determine whether this system would 
produce a luminescence reading on Day 3 using the FLUOstar OPTIMA. This 
experiment was carried out in six-well plates to optimize experiment. When cells reached 
approximately 90% confluency, a volume of 200 μL of cells was plated/well. This was an 
experimental value based on the size of a six-well plate. Cells were incubated at 37° C, 
5% CO2, and 100% humidity for optimal cell growth [26]. Cells, except control,  were 
then transfected 24 hours later (Day 1) with a 6:1 ratio of FuGENE 6 to AGTR1 based on 
the recommended guidelines by the FuGENE 6 transfection agent, allowing  AGTR1 to 
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be transected inside the cells. The media was removed, and treatment or supplemented 
media was added after being transfected for 24 hours (Day 2). This was a change to the 
PRESTO-TANGO method based on the methods for the PRESTO-TANGO system [26].  
Finally, after another 24 hours (Day 3), luminescence readings were taken using 
the FLUOstar OPTIMA machine. This involved removing media, adding 100 μL of 
Bright-Glo, incubating for 5 minutes (in the dark) on plate shaker and then transferring to 
a 96-well plate to read in the machine. These experimental steps were based on previous 
steps in the literature [26, 45]. The setting that was chosen for a snapshot reading was one 
cycle with a cycle time of 1 second and a measurement interval time of 4.06 seconds. 
This again was an experimental setting. It should be noted that the time frame of 24 hours 
between each day was selected based on previous literature on transfection, TANGO, and 
the PRESTO-TANGO methods [26, 45].  
When this experiment was first run following the aforementioned guidelines, it 
showed that AGTR1 had almost a luminescence reading 40 times higher than that of the 
nontransected control cells (Figure 8). However, when combined with losartan, the 
luminescence reading was decreased (Figure 9), indicating that AGTR1 was being 
activated on its own (Figure 9). Because AGTR1 was being activated, the concern was 
that it would be difficult to examine the effect of treatments on AGTR1 if AGTR1 on its 
own was being activated and produced such a high luminescence (Figures 8 & 9).  
The next step in the optimization process was to reduce AGTR1’s luminescence 
readings. It was first thought that an ingredient in the supplemented media might have 
been activating the AGTR1 receptor, specifically, the FBS. Although FBS provides 
nutrients to cells, it can contain unknown ingredients because it has been poorly defined 
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[46]. An unknown compound in the FBS was thought to be what might have caused an 
increase in AGTR1 activation because it was the most undefined ingredient in the 
supplemented media.  
Reducing the amount of FBS in the supplemented media showed that the 
luminescence readings of AGTR1 decreased (Figures 10 & 11). However, with the 
decrease in AGTR1’s luminescence readings, there also was a decrease in cell density. 
As shown in Table 1, the cell density decreased as there was a decrease in the FBS 
percentage in the supplemented media, but the viability of the cells was high. Because the 
cells were largely unaffected as viability of all cells being over 93%, it was thought that 
the cells were growing slower because fewer nutrients were being added to the 
supplemented media. To keep the nutrients high, with 10% FBS being added to the 
media, filter sterilized and dialyzed media was tested. The literature suggested that this 
may remove small undefined compounds from FBS [45, 47]. However, these methods 
did not reduce AGTR1 luminescence values; instead, they produced an increased 
response (12 & 13), indicating that AGTR1 was being activated still.  
The next step in the optimization process was to reduce the amount of AGTR1 
since the amount of FBS could not be reduced as it was thought to be affecting cell 
growth. Previously, the amount of 1 μg of AGTR1 was being used based on plate size 
and FuGENE 6 guidelines. However, reducing the amount of AGTR1 plasmid showed 
that lower amounts could reduce AGTR1 luminescence readings (Figures 14 & 15). 
While this was done, the settings on the FLUOstar OPTIMA also were changed to see if 
time affected the readings. Previously, only a snapshot reading had been taken, but by 
taking the reading over 10 min for 20 cycles with a cycle time of 30 seconds and a 
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measurement interval time of 1 seconds, a true reading could be shown. However, the 
half-life of the Bright-Glo™ Luciferase Assay System is 30 minutes and the readings 
over the 10 minutes indicated a constant decrease over the 10 minutes (Figure 15) [48]. 
This data suggested no difference between a snapshot reading or the average over the 10 
min, as shown in Figures 14 and 15, in which the trends between different AGTR1 
amounts were the same between the two figures. Therefore, the remainder of the 
experiments were carried out with a snapshot reading. In addition, based on the data, 0.1 
μg of AGTR1 was selected to be used for the remaining experiments because it reduced 
AGTR1 activation levels. Therefore, trials were transfected at a 60:1 ratio of FuGENE 6 
to AGTR1.  
The third step of optimization was to ensure that the system would work correctly 
by using the known agonist of Ang II and the known antagonist of losatan in the system. 
Both well-known compounds are used in the regulation of blood pressure and so were 
selected for this experiment. This system facilitated the detection of agonist of GPCRs 
through an increased luminescence signal. Thus, Ang II should have produced a 
luminescence greater than that of AGTR1, suggesting that AGTR1 was being activated 
by Ang II. In the case of losartan, no increased signal should have been displayed. First, 
Ang II was examined at the different time points to determine whether leaving the 
treatment on for longer periods of time would have affected the luminescence reading. As 
shown in Figure 16, Ang II luminescence readings did not fluctuate much between 6 and 
36 hours. It should also be noted that on Day 0, 250,000 cells were plated per well based 
on HEK293 cells, plate size and experimental values to reach 90% confluency by Day 3. 
Again, this was demonstrated in Figure 17, which indicated that the system was working 
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based on the luminescence values observed. Ang II had an increased average 
luminescence over AGTR1; losartan and the combination of Ang II had decreased values, 
suggesting that Ang II was activating the receptor and that it was working as the agonist. 
The decreased luminescence observed for the losartan treatments suggested that losartan 
was able to block the effect of Ang II and was working as an antagonist. The 
concentrations for Ang II and losartan showed good viability (Table 2). 
The final step was optimization of the treatments within the PRESTO-TANGO 
system. Optimization involved two steps: The first step was determination of resveratrol 
and pterostilbene concentration, and the second step was normalization of the cell 
densities. Based on the system thus far, the experiment was tried with various 
concentrations of resveratrol that included 50, 100, and 200 μM. The results of using 
various concentrations suggested that resveratrol did not produce activation when 
combined with AGTR1, but may have when combined at low dose concentrations (50 
μM) with Ang II (Figure 18). A cell count indicated that the cells that received treatment 
had a decreased cell count compared to that of the control and AGTR1. Therefore, the 
effect of resveratrol could not be determined at that time. The viability of the cells was 
still greater than 94%, suggesting that cell concentrations were not killing the cells (Table 
3). This same experiment was conducted again with various concentrations of 
pterostilbene, but because pterostilbene was a newer compound, there was less 
information available. Therefore, a range of concentrations suggested from other cell 
lines was created that contained the concentrations of 20, 40, 60, and 100 μM [49, 50]. 
Concentrations of 60 μM and 100 μM were eliminated because of the dramatic change in 
cell morphology. Based on a similar morphology and cell density to AGTR1, the 
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concentration of 20 μM was selected (Table 4). Based on Figures 19 and 20, average 
luminescence readings suggested that pterostilbene did not cause AGTR1 activation at 20 
μM, but with the addition of Ang II, pterostilbene did (Figure 20). Cell densities 
decreased with treatments compared to that of AGTR1 (Table 5). Therefore, the effect of 
pterostilbene could not be determined at the time. The viability of the cells was still 
greater than 95%, suggesting that cell concentrations were not killing the cells at 20 μM. 
The final part of the optimization was normalization of cell densities with 
treatments. As indicated previously, the effect of resveratrol and pterostilbene could not 
be determined because cell densities were not similar between AGTR1 and treatments. If 
the cell counts were not similar, results might not have been accurate because fewer cells 
were producing luminescence in the treatment wells. This could not confirm whether the 
receptor was being or not being activated. It was originally thought that based on the 
viability of the cells being high, treatment wells were growing slower. To confirm this 
hypothesis, a BrdU test was performed, which allows the proliferation of cells to be 
examined. These results indicated that the proliferation of treatments was higher than that 
of the control (see Appendix). This meant that the cells might have been growing faster 
and thus detaching in the treatment groups. Therefore, cell counts could have been lower 
for the treatment groups because the cells could have been lost during the counting stage.  
The experiment was optimized to BrdU format, growing cells in 100 x 20 mm dishes and 
splitting the cells between Day 2 and Day 3 into six-well plates to reach a 80% 
confluency by Day 3 (see Methods section). This experiment was run once more based 
on the Methods section, which produced cell densities similar between treatments, 
AGTR1 and control with a viability of greater than 97% (Table 6). It also was verified 
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that it could run in the FLUOstar OPTIMA with 80% confluency on Day 3 (Figure 21). 
Luminescence values were read using the FLUOstar for one cycle with a cycle time of 1 
second and a measurement interval time of 4.06 sec. The average luminescence for 
control had a value of 13,002, whereas AGTR1 had an increased value of 57,624 (Figure 
21). This indicated that the addition of AGTR1 to the cells created a higher luminescence 
reading, although in close proximity to the control. Ang II had an increased average 
luminescence reading of 98,656, as did resveratrol at 100 μM (Figure 21). This indicated 
that Ang II and resveratrol activated the AGTR1 receptor. The highest increased average 
luminescence was resveratrol + Ang II, with a value of 163,183 (Figure 21), thus 
confirming the activation of AGTR1. Losartan showed a decreased average luminescence 
to AGTR1 at a value of 26,601 (Figure 21), indicating that it did not activate AGTR1. 
4.2 Optimized System  
Once the system had been optimized with AGTR1 and treatments, it was run four 
times with triplicates for each condition. The optimized steps, as indicated in the Methods 
section, included using 10% FBS containing media, using a AGTR1 plasmid 
concentration of 0.1 μg, splitting cells between Day 2 and Day 3 for optimal confluency, 
and taking a snapshot reading. The conditions included control, AGTR1, Ang II, losartan, 
resveratrol 50 μM, resveratrol 100 μM, resveratrol 200 μM, resveratrol 50 μM + Ang II, 
resveratrol 100 μM + Ang II, resveratrol 200 μM + Ang II, pterostilbene 20 μM, and 
pterostilbene 20 μM+ Ang II,. In addition to the treatment groups, pGL4.54, a control 
plasmid that is constantly expressed using Bright-Glo, was included. As shown in Figure 
22, 0.1 μg of pGL4.54 was selected for this experiment because it was a middle number 
in the dilution series.  
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Tables 7, 8, 9, and 10 indicated that for all four trials, cell densities were similar. 
Luminescence readings were standardized to pGL4.54 for each of the four trials. The 
average of each group was then taken for each trial, and then those averages were 
combined to produce Figure 23. AGTR1 (0.73) increased from control (0.07). The 
treatment groups, in comparison to AGTR1, showed an increase with Ang II (1.09), a 
decrease with losartan (0.23), and a decrease with Ang II + losartan (0.21). This result 
indicated that Ang II activated AGTR1, having an agonist effect, and that losartan did not 
activate the receptor, but could block Ang II from binding, having an antagonist effect. 
However, the results were not statistically significant. 
Resveratrol groups of 50 μM (0.92), 100 μM (0.94), and 200 μM (1.2) showed an 
increase above AGTR1, with 200 μM being slightly higher than others (Figure 23). This 
increase indicated that resveratrol on its own actually activated AGTR1, thus having an 
agonist effect. Resveratrol 50 μM (1.27), 100 μM (1.36), and 200 μM (1.05) + Ang II 
groups showed an increase above AGTR1 and were higher then  resveratrol groups, with 
the exception of Ang II + 200 μM,  thus confirming that resveratrol activated the 
receptor, having an agonist effect (Figure 23). Resveratrol 50 μM and 100 μM with Ang 
II were higher than Ang II alone indicating an increased activation. However, the results 
were not statistically significant. 
Pterostilbene (0.75) remained similar to AGTR1, indicating that pterostilbene at 
20 μM did not activate the receptor (Figure 23). When pterositlbene was combined with 
Ang II, it had a large increase above AGTR1 (1.28), indicating an agonist effect (Figure 
23). The combination also was higher than Ang II alone, indicating that pterostilbene, 
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when combined with an agonist, produced an increased activation. However, the results 
were not statistically significant.  
These results suggested that resveratrol and pterostilbene did not produce a 
decreased luminescence compared to that of AGTR1. In fact, the results suggested that 
they activated AGTR1 when combined with Ang II. Although not statistically significant, 
these results suggested that resveratrol and pterostilbene do not block Ang II and do not 
work through the AGTR1 receptor to reduce blood pressure. Therefore, they may be 
working through another GPCR to reduce blood pressure if they do indeed reduce blood 
pressure. Based on the results obtained, pterostilbene may be more toxic to the cells, but 
















Chapter 5: Conclusion 
 Hypertension is a serious medical condition that can have detrimental 
consequences. Investigating alternative treatment options with the natural compounds of 
resveratrol and pterostilbene offered the possibility of reducing the side effects associated 
with drugs. GPCRs, are important targets for drugs, so understanding how these 
compounds work at the receptor level will help to explain how they can reduce blood 
pressure. This study examined resveratrol and pterostilbene at the receptor level using the 
PRESTO-TANGO method for the first time, focusing on the angiotensin II receptor type 
1 (AGTR1). Results indicated that that resveratrol at concentrations of 50 μM, 100 μM, 
and 200 μM activate the receptor and also when combined with Ang II, indicating an 
agonist effect. Ang with resveratrol 50 μM and 100 μM had a greater activation then Ang 
II alone. It was also found that pterostilbene 20 μM combined with Ang II activated 
AGTR1 and has a greater activation then Ang II alone. Although the results were not 
statistically significant, the trends suggested that resveratrol and pterostilbene do promote 
AGTR1 activation. Future studies will be needed to investigate these compounds further 
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Chapter 7: Appendix 
7.1 Formulas 
7.1.1 Cell Density  
Cell Density (cells/ml) = Average count per square x dilution factor x 10
4 
[51] 
*Average count = # of cells combination (viable + non-viable) 
7.1.2 Cell Viability  


















7.2. BrdU Results  
All supplementary data is reported as n = 1 for BrdU results. 
7.2.1 Control 
 










7.2.2 Angiotensin II  
 










7.2.3 Losartan  
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7.2.5 Resveratrol 50 μM  
 









7.2.6 Resveratrol 100 μM  
 









7.2.7 Resveratrol 200 μM  
 
 









7.2.8 Resveratrol 400 μM  
 










7.2.9 Angiotensin II + Resveratrol 50 μM  
 









7.2.10 Angiotensin II + Resveratrol 100 μM  
 









7.2.11 Angiotensin II + Resveratrol 200 μM  
 











7.2.12 Angiotensin II + Resveratrol 400 μM  
 
Figure 12. BrdU result for Ang II + resveratrol 400 μM with AGTR1. 
 
 
 
